MicroRNAs as prognostic markers in ovarian cancer

Marta Llauradó, Blanca Majem, Tatiana Altadill, Lucia Lanau, Josep Castellví, Jose Luis Sánchez-Iglesias, Silvia Cabrera, Javier De la Torre, Berta Díaz-Feijoo, Asuncion Pérez-Benavente, Eva Colás, Mireia Olivan, Andreas Doll, Francesc Alameda, Xavier Matias-Guiu, Gema Moreno-Bueno, Mark S. Carey, Josep Maria Del Campo, Antonio Gil-Moreno, Jaume ReventósMarina Rigau

Research output: Contribution to journalReview articleResearchpeer-review

26 Citations (Scopus)


Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment. Mechanisms of chemoresistance in cancer cells may be associated with mutational events and/or alterations of gene expression through epigenetic events. Although focusing on known genes has already yielded new information, previously unknown non-coding RNAs, such as microRNAs (miRNAs), also lead insight into the biology of chemoresistance. In this review we summarize the current evidence examining the role of miRNAs as biomarkers of response and survival to therapy in OC. Beside their clinical implications, we also discuss important differences between studies that may have limited their use as clinical biomarkers and suggest new approaches. © 2014 Elsevier Ireland Ltd.
Original languageEnglish
Pages (from-to)73-84
JournalMolecular and Cellular Endocrinology
Issue number1-2
Publication statusPublished - 5 Jun 2014


  • Chemotherapy
  • MiRNAs
  • Ovarian cancer
  • Prediction
  • Prognosis
  • Tumor resistance


Dive into the research topics of 'MicroRNAs as prognostic markers in ovarian cancer'. Together they form a unique fingerprint.

Cite this